Alvaro A. Martinez, Jose A. Gonzalez, Andrew K. Chung, et al.
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de noviembre del 2001
Reviewers: Li Liu, MD
Source: Cancer, Volume 88, 425-432 (January) 2000.
Despite significant improvements in the treatment of localized prostate cancer, the optimal management of this malignancy remains undefined. Currently, both radiation therapy (RT) and radical prostatectomy (RP) are used as primary treatment for certain groups of patients. However, it has been a long debate which treatment is superior. Since the introduction of serum prostate-specific antigen (PSA) levels to both stage and monitor patients after treatment, serious concerns have been raised as to the validity of data derived prior to the PSA era. In this study, the researchers reviewed the outcome of patients with localized prostate carcinoma who had a serum PSA value no higher than 10ng/ml and a Gleason score no higher than 6.
With a median follow-up period of 5.5 years:
In this study, radical prostatectomy and radiation therapy were fund to be equally effective in treating patients with low-risk prostate cancer. Due to the long natural history of prostate carcinoma and the potentially significant comorbidities in this patient population, longer follow-up is needed to analyze survival differences.